Introduction {#S1}
============

Gut microbes, an essential part of the microbiota ecosystem, outnumbers human cells by 10-fold ([@B111]). The gut microbiota contains bacteria, fungi, archaea, and protozoa and can be altered by the host genetics, overuse of antibiotics, and changes in diet, as described in the accompanying review ([@B6]; [@B75]). The most abundant phyla in human intestine were *Firmicutes*, *Bacteroidetes*, *Proteobacteria*, and *Actinobacteria* ([@B97]). *Firmicutes* are gram-positive bacteria including the large class of *Clostridia* and the lactic acid bacteria. Lactic acid bacteria are marketed as probiotic which are benefit for human health. Another sort of gram-positive bacteria are *Actinobacteria*, which include *Collinsella* and *Bifidobacterium* spp. *Bifidobacteria* is the other probiotic, which has been made in functional foods. Conversely, *Bacteroidetes*, and *Proteobacteria* are gram-negative bacteria, and LPS on their surface can induce activation of macrophages toward pro-inflammatory phenotype. Both can cause infection or diseases under certain conditions. The gut microbiota plays such a critical role in human health and disease that it has been called the "forgotten organ" ([@B69]). During millions of years of coevolution, the gut microbiota has been living in a symbiotic relationship with the host and affecting the energy balance ([@B4]). In addition, symbiotic bacteria promote the intestinal immune system maturity ([@B64]) and protect against pathogen colonization ([@B41]). Changes in the gut microbial composition result in chronic inflammation and metabolic dysfunction, as has been reviewed elsewhere ([@B90]). It is worth noting that the microbiota metabolites, short-chain fatty acids (SCFAs), play a key role in colonic inflammation ([@B108]). Many studies have shown that not only epithelial cells or neutrophils but also monocytes and macrophages are modulated by SCFAs ([@B13]).

Inflammation is a normal physiological response of the body to the foreign pathogen invasion and plays two conflicting roles in human health ([@B105]). On the one hand, inflammation is the body's automatic defense response, which also promotes wound healing. On the other hand, excessive inflammatory response results in a series of diseases such as obesity, atherosclerosis, and cancer, which has been reviewed in elsewhere ([@B103]; [@B25]; [@B14]). During acute inflammation, neutrophils are recruited to the inflamed tissue sites, while during chronic inflammation, lymphocytes, macrophages, and plasma cells accumulate and infiltrate the junction tissue ([@B32]). There is growing awareness that many prevalent diseases are linked to chronic inflammation. Thus, it is important to regulate inflammation in a timely manner to control the morbidity from disease ([@B98]).

Macrophages are regarded as critical effectors of inflammation. Resident tissue macrophages perform specific functions in response to their local environment ([@B39]). For example, macrophages are Kupffer cells in the liver and microglia in the central nervous system (CNS). Historically, blood monocytes exit the blood, enter tissues and undergo terminal differentiation to become tissue-resident macrophages ([@B27]). More recently, evidence has shown that tissue-resident macrophages, including lung macrophages and Kupffer cells, are established before birth and complemented by recruited monocytes under inflammatory conditions ([@B107]). They express pattern recognition molecules, such as Toll-like Receptor (TLR) 4, to recognize foreign pathogens, remove foreign molecules, and protect against infection ([@B30]). In addition, they respond to the inflammatory stimuli and differentiate into classically ("M1") or alternatively ("M2") activated macrophages. As reviewed by [@B32] macrophages infiltrate tissues during inflammation and perform major functions, including antigen presentation, phagocytosis, and production of various cytokines and growth factors to participate in immune regulation. It is worth mentioning that macrophages are pro-inflammatory under the Lipopolysaccharides (LPS) stimulation ([@B24]).

In this review, we summarize the current understanding of the link between gut microbiota and inflammation focusing on the roles of macrophages. In particular, we discuss two major inflammatory diseases, obesity and inflammatory bowel disease (IBD), and provide a description of the macrophages as the immune and inflammatory effector cells.

Gut Microbiota and Inflammation {#S2}
===============================

The gut microbiota and its metabolites may regulate the host inflammatory conditions ([@B106]; [@B21]). Numerous studies have linked the gut microbiota to inflammatory diseases. [@B22] have demonstrated that the immune-mediated inflammatory diseases, such as Crohn's disease (CD), ulcerative colitis (UC), multiple sclerosis (MS), and rheumatoid arthritis (RA), change the composition of the gut microbiota. In addition, there are abundant reports highlighting the gut microbiota role in the pathogenesis of the inflammatory diseases such as asthma, type 1 and type 2 diabetes mellitus (DM), and obesity ([@B3]; [@B47]; [@B65]).

The 16S ribosomal RNA (rRNA) sequencing paved the way for comparing the gut microbiota composition among individuals, which revealed the correlation between specific microbes and disease ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). *Enterobacteriaceae*, a large class of gram-negative facultative bacteria, are commonly linked to many inflammation diseases like IBD and obesity ([@B109]). For example, adherent-invasive *E. coli* (AIEC) has been associated with CD, while diffusely adherent *E. coli* (DAEC) has been linked to UC ([@B66]). In addition, the depletion of the phyla *Firmicutes* and the increase of the *Proteobacteria* populations have been linked to human IBD ([@B63]). Moreover, an increase in the ratio of *Firmicutes* to *Bacteroidetes* populations has been associated with obesity ([@B99]). [@B110] reported that the high levels of the phylum *Firmicutes* and the class *Clostridia* are found in diabetic patients. [@B112] found that children with non-alcoholic steatohepatitis (NASH) had a significantly higher proportion of *Proteobacteria*. Additionally, the gut microbiota of the RA patients contained higher levels of *Lactobacillus* and *Prevotella copri* and, correspondingly, the numbers of *Bifidobacteria* and *Bacteroides* decreased ([@B55]; [@B83]; [Supplementary Table S1](#TS1){ref-type="supplementary-material"}).

Short-chain fatty acids the major metabolic products of the gut microbiota digestion of the non-absorbable dietary fiber and resistant starches, included acetate, propionate, and butyrate ([@B46]). In addition to providing energy for the host, SCFAs exhibit anti-inflammatory effects via binding to G-protein-coupled receptor 43 (GPR43) ([@B62]), which is expressed in immune cells, including macrophages ([@B50]; [@B85]). Butyrate is the most important SCFA due to its role in antagonizing colonic inflammation ([@B33]) and the ability to meet 6--10% of the daily human energy requirements ([@B7]). *Ruminococcaceae*, *Eubacterium*, *Clostridia*, and *Firmicutes* were identified as the main producers of butyrate ([@B70]). Moreover, butyrate can exert an anti-inflammatory effect in part by suppressing the activation of NF-κB ([@B58]), a transcription factor that regulates the inflammatory and innate immune responses ([@B43]). In addition, butyrate strongly inhibits the interferon-gamma (IFN-γ) signaling to ameliorate inflammation ([@B45]). Butyrate also targets peroxisome proliferator-activated receptor-γ (PPARγ) to prevent colon inflammation ([@B44]).

###### 

Factors that influence composition of gut microbiota.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Factor          Classification      Research object                               Effects on gut microbiota                                                         References
  --------------- ------------------- --------------------------------------------- --------------------------------------------------------------------------------- --------------------------------
  Host genetics                       Twin pairs                                    Heritable microbes: *Christensenellaceae Methanobrevibacter smithii* (MZ \> DZ)   [@B34]; [@B29]; [@B28]

                  Genetically obese   Mice                                          ↑ *Firmicutes*\                                                                   [@B99]
                                                                                    ↓ *Bacteroidetes*                                                                 

  Diet            High-fiber diet     Children from Europe and rural Africa.        ↑ *Bacteroidetes* (*Prevotella*)\                                                 [@B16]
                                                                                    ↓ *Firmicutes*                                                                    

                  High-beef diet      Ten human volunteers                          ↓ *Bifidobacterium*\                                                              [@B38]
                                                                                    ↑ *Bacteroides*\                                                                  
                                                                                    ↑ *Clostridia*                                                                    

                  High-fat diet       Human                                         ↑ *Bacteroides*                                                                   [@B104]

                                      Rats                                          ↓ *Lactobacillus*                                                                 [@B51]

                  High-sugar diet     Natural sugars-fed mice (glucose, fructose)   ↓ *Bacteroidetes*\                                                                [@B18]
                                                                                    ↑ *Proteobacteria*                                                                

                                      Artificial sweeteners-fed mice                ↑ *Bacteroides*\                                                                  [@B94]
                                                                                    ↓ *Lactobacillus*                                                                 

  Antibiotics     Macrolide           2--7-year-old Finnish children                ↓ *Actinobacteria*\                                                               [@B48]
                                                                                    ↑ *Bacteroidetes*\                                                                
                                                                                    ↓ *Proteobacteria*                                                                

                  clindamycin         18--45 years healthy volunteers               ↓ *lactobacilli*\                                                                 [@B78]
                                                                                    ↓ *bifidobacteria*                                                                

                  Vancomycin          Obese males with metabolic syndrome           ↓ gram-positive bacteria (mainly *Firmicutes*)\                                   [@B101]
                                                                                    ↑ gram-negative bacteria (mainly *Proteobacteria*)                                

  Inflammation    RA                  Human                                         ↑ *Lactobacillus*\                                                                [@B55]; [@B83]
                                                                                    ↑ *Prevotella copri*\                                                             
                                                                                    ↓ *Bifidobacteria*\                                                               
                                                                                    ↓ *Bacteroides*                                                                   

                  IBD                 Human                                         ↓ *Firmicutes*\                                                                   [@B15]; [@B23]; [@B20]; [@B63]
                                                                                    ↓ *Bacteroidetes*\                                                                
                                                                                    ↑ *Proteobacteria*\                                                               
                                                                                    ↑ *Adherent-invasive Escherichia coli* (AIEC)                                     

                  TRUC                Mice                                          ↓ *Firmicutes* (*Clostridium*)\                                                   [@B26]
                                                                                    ↑ *Bacteroidales*\                                                                
                                                                                    ↑ *Proteus mirabilis*\                                                            
                                                                                    ↑ *Klebsiella pneumoniae*                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RA, Rheumatoid arthritis; IBD, inflammatory bowel disease; TRUC, T-bet-/- RAG2-/- ulcerative colitis.

Macrophages and Inflammation {#S3}
============================

Macrophages have been considered to be the central effector cells in many chronic inflammatory diseases ([@B67]). Macrophages have high functional plasticity ([@B92]) and exhibit pro- or anti-inflammatory properties in response to various cytokines and microbial products ([@B61]). In the early 1990s, scientists found that interleukin (IL)-4 exerts different effects on macrophage phenotypes compared to IFN-γ and/or LPS, and the concept of alternatively activated macrophages has been proposed ([@B91]). Since then, macrophages have been divided into two groups: classically activated M1 phenotypes, which are stimulated by IFN-γ and LPS and exert pro-inflammatory effects, and alternatively activated M2 phenotypes, which are stimulated by the IL-4 or IL-13 and perform anti-inflammatory functions, as reviewed by [@B96].

Many studies have been focused on applying the macrophage phenotype changes to the treatment of inflammatory diseases. For instance, atherosclerosis is a chronic inflammatory disease in which macrophages play a major role at all stages ([@B95]). [@B72] reported that miR-33 antagonizes atherosclerosis partly through promoting the M2 macrophage polarization. In addition, macrophages are associated with obesity-associated inflammatory diseases of the adipose tissue ([@B102]). A study by [@B59] illustrated that adipose tissue macrophages (ATMs) switch from the M1 polarized macrophage to the M2 polarized macrophage, thereby reducing the adipose tissue-derived inflammatory signals ([@B59]). Additionally, the RA was found to be closely related to the imbalance of the M1 and M2 macrophages and could be attenuated by reestablishing the macrophage equilibrium ([@B54]). Identically, IBD could be ameliorated via the M1 to M2 switch in the colitis mouse model ([@B113]). These findings suggest a strong correlation between macrophages and the inflammatory diseases and imply that macrophages participate in the inflammatory process mainly by shifting from the pro-inflammatory (M1) to anti-inflammatory (M2) phenotype ([@B76]).

Macrophages Are Involved in the Interaction Between the Gut Microbiota and Obesity {#S4}
==================================================================================

Obesity is a state of low-grade chronic inflammation, characterized by the expanded adipose tissue (AT) in which macrophages account for 1--30% of its composition ([@B37]). As reviewed by [@B80], adipose tissue macrophages (ATMs) include tissue-resident and monocyte-derived macrophages, and the increased number of ATMs in AT is mainly due to the recruitment of blood-macrophages and proliferation of resident macrophages. ATMs are the major effectors of the adipose tissue inflammation; ATMs accumulate in AT to participate in the inflammatory pathways, such as increasing the adipose tissue production of pro-inflammatory cytokines ([@B102]). Since scientists have found that the composition of the gut microbiota is significantly different between the lean mice and the obese mice, the latter showing lower *Bacteroidetes* and higher *Firmicutes* bacteria ([@B53]) levels, people began to realize the close connection between the gut microbiota and obesity. Subsequently, the gut microbiota has been found not only responsible for the weight gain and energy harvest ([@B81]), but also involved in the development of the low-grade inflammation associated with obesity ([@B9]).

Accumulating evidence indicates that alterations in the gut microbiota are responsible for the progression of obesity. There are two possible pathways of the gut microbiota affecting obesity and the obesity-related diseases, such as diabetes and cardiovascular diseases: the circulation of bacterial components (e.g., LPS) and metabolites SCFAs ([@B36]) ([Figure 1](#F1){ref-type="fig"}). The obesity-associated decrease in the *Bifidobacterium* levels leads to the reduced production of GLP-2, a key molecule that promotes the intestinal barrier function, eventually destroying the tight junction integrity of the epithelial barrier and enhancing the intestinal permeability ([@B10]). Under these circumstances, LPS enters circulation through passive diffusion across the intestinal mucosa ([@B36]). In addition, [@B8] found that the conventionally raised (CONV-R) mice showed increased plasma LPS concentrations compared with the germ-free (GF) mice, both mildly obese. Moreover, gut-derived LPS promoted macrophage accumulation in the adipose tissue ([@B8]) and increased the proliferation of the ATMs via a CD14-dependent pathway ([@B57]). In AT, macrophages recognized LPS through the TLR4 receptor, which is expressed on the cell surface, thereby converting from the M2 phenotype to the M1 phenotype and subsequently secreting pro-inflammatory cytokines, such as IL-1β and TNF-α, to participate in the inflammatory response ([@B102]; [@B74]; [@B35]). Similarly, some reports reveal that the lack of TLR4 attenuates the adipose tissue inflammation by shifting the ATM polarization toward the M2 phenotype ([@B71]). In addition, the level of SCFAs was found to be higher in the obese compared with the normal-weight children due to the differences in the gut microbiota ([@B77]; [@B79]). Conversely, the HFD-fed mice displayed decreased SCFAs levels ([@B56]). Abundant reports indicate that macrophages are involved in the SCFA-mediated anti-inflammatory effects in obesity. For example, propionic acid, a major SCFA, prevents the obesity-related inflammation partially through acting on macrophages ([@B2]). *In vitro* studies have demonstrated that butyrate could inhibit the LPS-mediated macrophage migration via the suppression of Src ([@B60]). Also, the circulating acetate level was increased by the antibiotic use in HFD-fed mice, reducing macrophage infiltration via activating AMPK ([@B11]).

![Macrophages are involved in the interaction between gut microbiota and IBD or Obesity. **(A)** Under gut homeostasis, bone marrow derived Ly6C^+^ monocytes are constantly recruited to gut to replenish the intestinal macrophages (CD14^--^ macrophages) which recognize the pathogen through TLR4 receptor and secret anti-inflammatory cytokine IL-10 to promote Treg cell expansion. **(B)** In IBD, the inflammatory environment lead to gut dysbiosis included increased number of AIEC which can survive and replicate in macrophages, and decreased butyrate bacteria like *Ruminococcaceae*, *Eubacterium*, *Clostridia*, and *Firmicutes*, which impairs the ability of butyrate exert anti-inflammatory role through inhibiting HDACs/NF-κB (GPR43/41) or promoting IL-10 secretion (GPR109a). Additionally, blood Ly6C^+^ monocytes are recruited to intestinal to become inflammatory macrophages (CX3CR1^+^ macrophages) and secrete pro-inflammatory cytokines such as IL-23 and TNF-α to participated in inflammatory response. **(C)** In Obesity, the alteration of gut microbiota composition caused by HFD-diet lead to an increase of intestinal permeability, therefore LPS enter system circulation (i.e., metabolic endotoxemia). Adipose tissue macrophages are response to LPS activation and transform to M1 phenotype.](fmicb-11-01065-g001){#F1}

Macrophages Are Involved in the Interaction Between the Gut Microbiota and IBD {#S5}
==============================================================================

Inflammatory bowel disease, which includes UC and CD, is a persistent inflammatory disorder of the intestine. It is becoming increasingly appreciated that the gut dysbiosis is linked to the pathogenesis of IBD ([@B68]). Under normal conditions, the mucosal immune system is precisely controlled to protect the intestines from the pathogenic bacteria infections and simultaneously maintain the immunological tolerance to benefit the gut microbiota, as described in the accompanying review ([@B1]). The disruption of normal mucosal immunity toward the commensal microbiota leads to continuous microbial antigenic stimulation and contributes to chronic intestine inflammation ([@B93]). In IBD, the numbers of the commensal bacteria (predominantly *Firmicutes* and *Bacteroidetes*) were reduced ([@B23]), and the numbers of the facultative anaerobic bacteria of the family *Enterobacteriaceae* were increased ([@B114]). Furthermore, the levels of the microbiota metabolites, the SCFAs, decreased along with the reduction in the population of *Clostridium IXa* and *IV* groups, the main butyrate-producing bacteria ([@B20]), limiting intestinal inflammation by regulating the function of colonic T cells (Tregs) ([@B88]). In a word, the inflammation-related disruption of the host-microbe interactions and decrease in the SCFA levels are involved in the development of IBD ([Figure 1](#F1){ref-type="fig"}).

Intestinal macrophages, which reside in the lamina propria, are among the most abundant immune cells in the gut ([@B52]) and the first line of defense against the invasion of foreign pathogens ([@B89]). Unlike blood monocytes or other tissue-resident macrophages, intestinal macrophages do not respond to LPS due to the absence of CD14, a surface receptor that plays a key role in the LPS-induced cell activation; hence, the LPS-induced pro-inflammatory cytokine production (IL-1, IL-6, IL-8, and TNF-α) is markedly reduced ([@B100]; [@B87]; [@B89]). Moreover, intestinal macrophages produce anti-inflammatory cytokines like IL-10 and further regulate T-cell differentiation to prevent mucosal auto-inflammation ([@B17]). Although human intestinal macrophages exhibit profound "inflammatory anergy," they retain strong phagocytic activity and perform defense functions ([@B89]). Since intestinal macrophages perform such essential functions, they are integral to maintaining intestinal homeostasis. [@B42] identified a unique CD-specific macrophage subset that expresses high levels of CD14 and produces pro-inflammatory cytokines, such as IL-23 and TNF-α, leading to the accumulation of pro-inflammatory macrophages. In other words, there are "resident" and "inflammatory" macrophages in the gut that share the same Ly6Chi monocyte precursors under different conditions ([@B5]).

Although there is a current consensus that gut dysbiosis is closely linked to IBD, it should not be concluded that there is a direct causal relationship between them ([@B68]). However, it is clear that intestinal inflammation can alter the composition of the gut microbiota, which further exacerbates inflammation ([@B75]). Macrophages are well established as the innate immune system cells that recognize invading microbiota using pattern recognition receptors and exhibit efficient phagocytic and bactericidal activity ([@B40]). Under normal conditions, intestinal macrophages rely on the commensal microbiota for the immune response, while in IBD, inflammatory macrophages are recruited to the inflamed tissue ([@B31]). Moreover, the impaired acute inflammatory response in CD leads to the delayed clearance of bacteria ([@B86]). Adherent-invasive *E. coli* (AIEC), the aggressive functionally altered resident strains in IBD, have the ability to invade intestinal epithelial cells (IEC) ([@B82]; [@B73]). Subsequently, AIEC is swallowed by macrophages and replicates inside them due to the defect in autophagy ([@B49]), which is involved in the pathogenesis of IBD. Additionally, the SCFA butyrate can exert anti-inflammatory effects via regulating the intestinal macrophage function as a histone deacetylase (HDAC) inhibitor ([@B12]) or suppressing the NF-κB activation ([@B58]). Furthermore, butyrate has the ability to exhibit anti-inflammatory activity on intestinal macrophages, which express Gpr109a by inducing the expression of IL-10 ([@B84]), while these functions are attenuated in IBD due to the decrease of butyrate concentration.

Conclusion {#S6}
==========

This review provides current understanding of the role of macrophages in gut microbiota and inflammation interactions. On the one hand, the polarization of macrophages, mediated by gut-derived LPS and its metabolites SCFA, plays a key role in the regulation of inflammatory diseases. On the other hand, macrophages are the main players in ensuring intestinal homeostasis through pathogen recognition and elimination and production of anti-inflammatory cytokines. Besides, a recent report by [@B19] revealed that a loss of intestinal macrophages influenced the establishment of the gut microbiota in zebrafish, which suggests a critical role of macrophages in shaping the gut microbiota. Taking into account the important role of macrophages in the relationship between gut microbiota and inflammation, developing macrophage-targeting approaches in the prevention and therapy of inflammatory diseases is an appealing strategy. However, the related molecular signaling pathways involved in the roles of macrophages between gut microbiota and inflammation diseases are remained to be defined. Further work is needed to apply macrophages as a perspective target in the treatment of gut microbiota-related inflammatory diseases, like obesity and non-alcoholic fatty liver.
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